Skip to main content
Fig. 3 | EJNMMI Research

Fig. 3

From: Bone marrow cell homing to sites of acute tibial fracture: 89Zr-oxine cell labeling with positron emission tomographic imaging in a mouse model

Fig. 3

Mobilization of BM cells using plerixafor reduces cell migration to the site of fracture. a The regimen of d1-fracture with a 3-day administration of plerixafor starting on day 1 and microPET/CT images are shown. 89Zr-oxine-labeled BM cells trafficked to the fracture site and the accumulation was observed on day 2 through day 5 (n = 4). b The regimen of d0-fracture with a 3-day administration of plerixafor starting on day 0 and microPET/CT images are shown. The 89Zr-oxine-labeled BM cells were transferred immediately after the fracture generation and administration of the first dose of plerixafor. Weak 89Zr signal was observed at the injury site from day 1 through day 5 (n = 4). c Quantitation of the d1-fracture-plerixafor PET images indicate that the percentage of 89Zr-labeled BM cells accumulated at the fracture was significantly higher than in the contralateral non-fractured tibia (n = 4). d Quantitation of the d0-fracture-plerixafor PET images show a slightly higher 89Zr-labeled BM cells accumulation at the fracture compared to the contralateral tibia (n = 4). (ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, two-way repeated measure ANOVA with Sidak’s test. The arrows indicate the timing of bone injury generation). e The peak accumulation on day 2 was reduced by plerixafor compared to non-mobilized mice in the d1-fracture-plerixafor scheme (n = 6). f Plerixafor significantly reduce the peak accumulation, on day 1 and 2, compared to the non-mobilized mice in the d0-fracture-plerixafor scheme (n = 6). (*p < 0.05 with Mann-Whitney test)

Back to article page